Detail akcie Kiniksa Pharma Rg online

Business Summary: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Kiniksa Pharmaceuticals Internationl PLC revenues increased 58% to $475.4M. Net income totaled $44.8M vs. loss of $34.3M. Revenues reflect Revenue increase of 61% to $475.4M. Net Income reflects biopharmaceutical company segment income totaling $57.5M vs. loss of $26.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to $0.61.